UPDATE: Teva's (TEVA) '302 Capaxone Patent Invalidated by U.S. Patent Office
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - September 1, 2016 2:51 PM EDT)
Teva Pharma (NYSE: TEVA) lost a third court ruling against Mylan (NASDAQ: MYL) related to Teva's drug Copaxone. Today's decision by the U.S. Patent and Trademark Office stated that claims 1-12 of the ’302 patent are held unpatentable. Previously two other patents were invalidated.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Wabtec (WAB), Faiveley Settle DOJ Merger Challenge with Divestiture - Bloomberg
- Zimmer Biomet Holdings (ZBH) Announces Statistical Superiority in Seven-Year Follow-up of Mobi-C vs. Two-Level ACDF
- Agilysys, Inc. (AGYS) Plans CEO Search; CFO Seebeck Resigns
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!